CDMOs face regulatory pressure to implement a Contamination Control Strategy (CCS) as required by the revised EU GMP Annex 1 (2022). The article argues that traditional contamination control programs are insufficient for multi-product facilities and proposes Contamination Control by Design (CCbD) as a structured methodology.
Key Details
- EU GMP Annex 1 (2022), effective August 2023, mandates a documented CCS for sterile manufacturers.
- FDA expectations are substantively equivalent; a CCS built to Annex 1 can satisfy both agencies.
- CDMOs operate multiple product streams through shared infrastructure, increasing contamination risk complexity.
The article identifies three weaknesses in current CDMO contamination control programs:
- Product-specific (not facility-wide) risk assessments
- Undocumented design decisions
- Environmental monitoring disconnected from risk
Contamination Control by Design (CCbD)
CCbD is a structured methodology for integrating contamination control into facility and process design. It complements existing frameworks (Eudralex, ICH Q7–Q10) without replacing them. The CCbD Standard is available free at www.ccbd.io.
CCbD aims to produce a living CCS that reflects actual contamination risk management, not a report assembled for inspections.